Clinical Trial Update: WOE of Anti-CD20 Therapies

View source ↗

Summary

A completed clinical trial update evaluating weight-of-evidence for anti-CD20 monoclonal therapies in multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)
• Ocrevus (ocrelizumab)
• Rituxan (rituximab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: COMPLETED